Citius Oncology, Inc. (NASDAQ: CTOR)

Citius Oncology, Inc. is a biopharmaceutical company headquartered in Cranford, New Jersey, focused on developing and commercializing innovative targeted oncology therapies. The company's lead product is LYMPHIR, an engineered IL 2 diphtheria toxin fusion protein approved by the FDA in August 2024 for the treatment of persistent or recurrent cutaneous T cell lymphoma. Citius Oncology aims to achieve a market leading position by leveraging its intellectual property, regulatory exclusivity, and a strategy that pairs direct U. S. sales with international partnership arrangements.

Revenue is generated primarily from the sale of LYMPHIR in the United States through a dedicated oncology sales force targeting major cancer centers. The company also expects to earn royalty income and milestone payments from out licensing arrangements for markets outside the United States. Additionally, Citius Oncology may receive development and commercial milestone payments under its license and asset purchase agreements with Eisai and Dr. Reddy’s.

Within the cutaneous T cell lymphoma treatment landscape, Citius Oncology competes with approved therapies such as mogamulizumab (Poteligeo), brentuximab vedotin (Adcetris), romidepsin (Istodax), and vorinostat (Zolinza). The company’s competitive advantages stem from LYMPHIR’s unique mechanism of action that both kills tumor cells and depletes immunosuppressive regulatory T cells, its orphan drug designation, and its inclusion in the National Comprehensive Cancer Network guidelines with a Category 2A recommendation. These factors, together with a newly assigned HCPCS J code (J9161), support differentiated positioning and potential reimbursement advantages.

The company serves prescribing hematologists, oncologists, and dermatologist oncologists at major cancer centers, as well as key opinion leaders and patient advocacy groups involved in cutaneous T cell lymphoma care. Distribution and logistics are supported by agreements with Cardinal Health, Cencora, McKesson Corporation, and the technology platform EVERSANA. For international access, Citius Oncology has entered into named patient programs with Integris Pharma S. A. covering Greece, Cyprus, Malta, Bulgaria, Romania, Croatia, Serbia, Albania, Bosnia Herzegovina, Kosovo, Montenegro, and North Macedonia.